18
approvals
in the US, EU and Japan
Our results
Total net sales
$46.2B
Consistent with prior year, or an increase of 3% when excluding foreign exchange
↑ 7%
In-line brand
YoY% growth
↑ 87%
New product portfolio*
YoY% growth
Potential for risk-adjusted sales of $10-$13B revenues in 2025
Potential for $25B+ of non-risk adjusted revenues in 2030
Delivered strong financial
and operational
performance
GAAP EPS1
$2.95
Non-GAAP EPS1,2
$7.70
Significant pipeline advancement in 2022
| 9 |
bms for Opdivo; Opdivo plusYervoy
5
positive registrational
topline readouts
$9.5B
invested in research
and development
Figures and data from the 2022 Bristol Myers Squibb Annual Report
3 first-in-class medicines launched
For metastatic melanoma
For obstructive hypertrophic cardiomyopathy
For moderate to severe plaque psoriasis
Strategically positioned for multiple waves of innovation
9
new products launched over
~3 years3
(2H 2019-2022)
| 15+ |
additional
indications
over ~3 years3
6
high potential mid-late
stage registrational assets
across therapeutic areas
| 50+ |
early-stage assets
in development
Figures and data from the 2022 Bristol Myers Squibb Annual Report
Balanced approach to capital allocation
$13.1B
in cash flow from operating activities
Reduced debt by
~$5B
Returned cash to shareholders
~$12.6B4
Figures and data from the 2022 Bristol Myers Squibb Annual Report
An interview with Elizabeth Mily:
How BMS is building broader
growth in 2023 and beyond
Bristol Myers Squibb’s growth over the past year has been driven by strategies that link the company’s longstanding strengths with the resources of new partners. We spoke with Elizabeth Mily, executive vice president for Strategy and Business Development, about the company’s approach to innovation, collaboration and growth this year — and beyond.
Significant product
approvals in 2022
| 18 | approvals in the |
|
JanuaryJapan’s Ministry of Health, Labour and Welfare approved Abecma for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior therapies. |
MarchJapan’s Ministry of Health, Labour and Welfare approved Opdivo for the adjuvant treatment of urothelial carcinoma. Japan’s Ministry of Health, Labour and Welfare approved Opdivo for the adjuvant treatment of urothelial carcinoma. FDA approved Opdualag, a fixed-dose combination of nivolumab and relatlimab, for the treatment of adult and pediatric patients 12 years of age and older with unresectable or metastatic melanoma. | AprilEuropean Commission (EC) approved Opdivo in combination with fluoropyrimidine and platinum-based chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC with PD-L1 expression ≥ 1%. EC approved Opdivo for the adjuvant treatment of adults with muscle-invasive urothelial carcinoma with tumor cell PD-L1 expression ≥ 1% who are at risk of recurrence after undergoing radical resection. EC approved Opdivo plus Yervoy for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic ESCC with tumor cell PD-L1 expression ≥ 1%. EC approved Breyanzi for the treatment of adult patients with relapsed or refractory diffuse B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B after two or more lines of systemic therapy. FDA approved Camzyos for the treatment of adult patients with symptomatic obstructive HCM. |
MayFDA approved Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment for adult patients with unresectable advanced or metastatic ESCC regardless of PD-L1 status. FDA approved Opdivo plus Yervoy as a first-line treatment for adult patients with unresectable advanced or metastatic ESCC regardless of PD-L1 status. Japan’s Ministry of Health, Labour and Welfare approved Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment for adult patients with unresectable advanced or metastatic ESCC regardless of PD-L1 status. Japan’s Ministry of Health, Labour and Welfare approved Opdivo plus Yervoy as a first-line treatment for adult patients with unresectable advanced or metastatic ESCC regardless of PD-L1 status. |
JuneFDA approved Breyanzi for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after one line of therapy who are not eligible for transplant or who relapsed within 12 months of first-line chemoimmunotherapy. | SeptemberEC approved Opdualag® for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumor cell PD-L1 expression < 1%. FDA approved Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Japan’s Ministry of Health, Labour and Welfare approved Sotyktu for the treatment of plaque psoriasis, generalized pustular psoriasis or erythrodermic psoriasis for patients who have had an inadequate response to conventional therapies. DecemberJapan’s Ministry of Health, Labour and Welfare approved Breyanzi for the second-line treatment of relapsed or refractory large B-cell lymphoma, regardless of whether autologous hematopoietic stem-cell transplantation is intended. |
2022 awards and recognition
World’s Most Admired
Companies
Fortune
Best for Vets Employers
Ranked No. 1
Military Times
2022 2022 ERG/BRG of the Year
DisabilityIN
100 Best Corporate Citizens
3BL Media
2022 Top Companies for
Executive Women
Seramount
Best Place to Work
BioSpace
Most Innovative Companies
Fast Company
Menopause Friendly
(Bristol Myers Squibb UK&I)
The Menopause Friendly Accreditation
100 Best Workplaces
for Innovators in 2022
Fast Company
Modern Board 25
Most innovative boards of directors
Fortune
America’s Top Corporations:
Resiliency Edition
Women’s Business Enterprise National Council (WBENC)
100 score on Corporate Equality
Index for #LGBTQ+ inclusive
policies and practices
Human Rights Campaign Foundation
References
* New product portfolio includes Reblozyl® (luspatercept-aamt), Inrebic® (fedratinib), Onureg® (azacitidine tablets), Zeposia® (ozanimod), Breyanzi® (lisocabtagene maraleucel), Abecma® (idecabtagene vicleucel), Opdualag® (relatlimab plus nivolumab), Camzyos® (mavacamten) and SotyktyuTM (deucravacitinib).
1 GAAP and non-GAAP EPS include the net impact of Acquired IPRD charges and licensing income of ($0.24) per share for the full year 2022. Acquired IPRD refers to certain in-process research and development (“Acquired IPRD”) charges resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights.
2 This Non-GAAP amount excludes certain costs, expenses, gains and losses and other specified items. A reconciliation of GAAP to non-GAAP measures can be found on our website at bms.com. See, “Quarterly package of financial Information” available on bms.com/investors for information on the list of specified items excluded from Non-GAAP EPS.
3 Portfolio achievements from 2H 2019-2022.
4 Includes $4.6 billion for dividends paid and $8.0 billion for common stock repurchases.